Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | HTR7 | P34969 | 4/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034993 | 0.85 | CACNA2D1 (0.48) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4032376 | 0.83 | ALDH1A1 (0.53) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4037091 | 0.83 | ENPP2 (0.46) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4036687 | 0.79 | ALDH1A1 (0.45) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL4032640 | 0.71 | ALDH1A1 (0.41) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4038814 | 0.71 | AGTR2 (0.44) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL6270691 | 0.70 | GAA (0.46) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4038343 | 0.69 | GAA (0.57) | KMT2AALDH1A1 | |
| SCHEMBL1381762 | 0.69 | GAA (0.49) | KMT2AALDH1A1KDM4E | |
| SCHEMBL4035592 | 0.69 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | HTR1A 30/4885HTR7 161/4885UTS2R 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.